Encompass Health (NYSE:EHC) Rating Reiterated by Raymond James

Raymond James reissued their strong-buy rating on shares of Encompass Health (NYSE:EHC) in a report released on Friday morning, Benzinga reports. The firm currently has a $95.00 target price on the stock, up from their previous target price of $85.00.

Several other equities research analysts have also commented on the company. Barclays upped their price objective on Encompass Health from $101.00 to $108.00 and gave the stock an overweight rating in a research report on Thursday. Mizuho increased their target price on Encompass Health from $93.00 to $95.00 and gave the company a buy rating in a research report on Thursday. Royal Bank of Canada reiterated an outperform rating and set a $83.00 target price on shares of Encompass Health in a research report on Friday, February 9th. William Blair reiterated an outperform rating on shares of Encompass Health in a research report on Wednesday, February 7th. Finally, Truist Financial increased their price objective on Encompass Health from $82.00 to $86.00 and gave the company a buy rating in a research note on Friday, February 9th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of Buy and an average price target of $86.56.

Encompass Health Price Performance

Shares of NYSE:EHC opened at $82.46 on Friday. Encompass Health has a twelve month low of $57.55 and a twelve month high of $85.84. The company’s 50 day moving average is $78.25 and its 200 day moving average is $70.87. The company has a current ratio of 1.37, a quick ratio of 1.28 and a debt-to-equity ratio of 1.14. The company has a market cap of $8.26 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 1.50 and a beta of 0.94.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the company earned $0.88 EPS. Encompass Health’s quarterly revenue was up 13.4% on a year-over-year basis. On average, sell-side analysts forecast that Encompass Health will post 4.04 EPS for the current year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Monday, April 1st were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date of this dividend was Thursday, March 28th. Encompass Health’s dividend payout ratio (DPR) is 16.22%.

Hedge Funds Weigh In On Encompass Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Securities Inc. purchased a new position in shares of Encompass Health in the 4th quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Encompass Health by 360.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after buying an additional 317 shares during the period. McGlone Suttner Wealth Management Inc. purchased a new position in shares of Encompass Health in the 4th quarter valued at about $30,000. GAMMA Investing LLC purchased a new position in shares of Encompass Health in the 4th quarter valued at about $33,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in shares of Encompass Health in the 3rd quarter valued at about $35,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.